ストックスクリーナーアプリを入手
13.04
0.23%
-0.03
前日終値:
$13.07
開ける：
$13.32
24時間の取引高:
92,895
Relative Volume:
0.84
時価総額：
$487.96M
収益：
$239.40M
当期純損益:
$104.44M
株価収益率:
4.4054
EPS:
2.96
ネットキャッシュフロー:
$-18.50M
1週間 パフォーマンス:
-2.98%
1か月 パフォーマンス:
-0.15%
6か月 パフォーマンス:
-20.78%
1年 パフォーマンス:
-1.95%
1日の値動き範囲:
$12.97
$13.40
1週間の範囲:
$12.70
$13.62
52週間の値動き範囲:
$11.35
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
名前
Entrada Therapeutics Inc
セクター
電話
857-305-1825
住所
ONE DESIGN CENTER PLACE, BOSTON
TRDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
13.04 | 487.96M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-01-05 | 開始されました | Oppenheimer | Outperform |
| 2023-04-03 | 開始されました | H.C. Wainwright | Buy |
Entrada Therapeutics Inc (TRDA) 最新ニュース
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Trading (TRDA) With Integrated Risk Controls - Stock Traders Daily
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
How the (TRDA) price action is used to our Advantage - Stock Traders Daily
Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says - Bloomberg Law
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025 - Nasdaq
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
(TRDA) Proactive Strategies - Stock Traders Daily
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
When (TRDA) Moves Investors should Listen - Stock Traders Daily
Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Acquires 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics : Corporate Presentation -January 15, 2025 at 04:41 pm EST - Marketscreener.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC - Defense World
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26% - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6%Here's Why - MarketBeat
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases - PR Newswire
Geode Capital Management LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC - MarketBeat
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Where are the Opportunities in (TRDA) - Stock Traders Daily
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
Charles Schwab Investment Management Inc. Has $2.97 Million Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics Inc (TRDA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):